CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with Type 2 Diabetes (T2DM): Pooled data from four pivotal phase III trials
DOI 10.1055/s-0034-1374999
Bibliografische Angaben
Nachweis in CareLit
Autor:innenT Hach, J Gerich, A Salsali, G Kim, S Hantel, HJ Woerle, UC Broedl
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe05/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background, methods: We analyzed pooled data from 2477 patients with T2DM (mean [SD] age 55.6 [10.2] years, HbA1c 7.99 [0.85]%, BMI 28.7 [5.5] kg/m2) from four randomized, placebo-controlled Phase III trials that investigated empagliflozin (EMPA) 10 mg or 25 mg given for 24 weeks as monotherapy, add-on to metformin (MET), add-on to MET + SU, or add-on to pioglitazone ± MET. Results: EMPA significantly reduced HbA1c…
Zitieren
Zitierempfehlung
T Hach, J Gerich, A Salsali, G Kim, S Hantel, HJ Woerle, UC Broedl (2014) Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with Type 2 Diabetes (T2DM): Pooled data from four pivotal phase III trials. Diabetologie und Stoffwechsel (05). https://doi.org/10.1055/s-0034-1374999
Mit CareLit weiterarbeiten